Clinical Data Reports Third Quarter Fiscal Year 2011 Operational and Financial Results

NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA) today announced operational and financial results for the third fiscal quarter ended December 31, 2010. The Company received approval from the U.S. Food and Drug Administration (FDA) of Viibryd™ for the treatment of adults with major depressive disorder (MDD) on January 21, 2011. In addition, Phase III development of Stedivaze, the Company’s coronary vasodilator for use in nuclear-SPECT myocardial perfusion imaging (MPI), is continuing with the initiation of a second Phase III trial anticipated in the second quarter of this calendar year.